Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform. A replay will be available on the Events & Presentations page of the company's investor relations website.
The conference appearance offers Helus Pharma an opportunity to engage with the investment community and highlight its progress in developing proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom, and Ireland.
The fireside chat comes at a critical time for the company as it advances its lead candidate through late-stage development. Investors and industry observers will be listening for updates on clinical timelines, regulatory pathways, and commercialization strategies. For those unable to attend in person, the live webcast and subsequent replay provide accessible ways to stay informed. More information about Helus Pharma can be found at www.helus.com. The full press release is available at https://ibn.fm/LrRvm.
The announcement was disseminated on behalf of Helus Pharma and may include paid advertising, with distribution facilitated by InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, delivering services such as editorial syndication to 5,000+ outlets and social media distribution to millions of followers. These channels help companies like Helus Pharma reach a wide audience of investors, influencers, and the general public. For more details on InvestorWire's services, including press release enhancement, visit https://www.InvestorWire.com. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
